COVID-19 Pfizer Information
Discover the Oncology Development Program and Clinical Trials
Pfizer Medical Information
LORVIQUA SMPC
LORVIQUA Website
XALKORI SmPC
XALKORI Website
VIZIMPRO SmPC
Digitally Empowered (a collaboration between Patient Empowerment Network and Pfizer)
Age: Addressing a Blind Spot in Cancer Care
Some Older People Living with Cancer Aim for Remission but Lack Needed Resources to Help Make Treatment Decisions
Global Medical Grants Oncology Brochure
Investigator Information and How to Contact Us
Business Development
Get it Done: Return to Cancer Screening Telehealth Guide for Patients - English Version
Get It Done: Return to Cancer Screening Telehealth Guide for Patients - Spanish Version
Get It Done: Return to Cancer Screening In-Person Guide for Patients – English Version
Get It Done: Return to Cancer Screening In-Person Guide for Patients – Spanish Version
Pfizer Oncology Patient Centricity Ecosystem: From Launch to Impact
Pfizer Oncology Collaborating to Improve Patient Centricity in Clinical Trials
What to Expect With Your Cancer Care During COVID-19
What to Expect With Your Cancer Care During COVID-19 – Spanish Version
Lung Narrative
This is Living with Cancer
Abstract Plain Language Summaries
Follow Us @PfizerOncMed
Thank you for finding us at ELCC 2022
Who We Are and What We Do
One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases
Thank you for finding us at ELCC 2022
Who We Are and What We Do
One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases
Learn About Our Oncology Approved Medicines
PF-06863135 is an investigational compound and has not been approved by any Regulatory Authority as safe or effective for any use. The preclinical and in vitro evidence presented here may not necessarily correlate with clinical outcomes.
